Belzutifan FDA Approval Status
Belzutifan (MK-6482) is a novel, potent and selective inhibitor of HIF-2α in development for the treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC).
Development Timeline for belzutifan
|Mar 16, 2021||Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.